Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1310-1317

  Chantry, Andrew D ^a   Snowden, John A ^b   Craddock, Charles ^c   Peggs, Karl ^d   Roddie, Claire ^e   Craig, Jenny I O ^f   Orchard, Kim ^g   Towlson, Keiren E ^h   Pearce, Rachel M ⁱ   Marks, David I ^j  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e Hemel Hempstead General Hospital   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

ⁱ BSBMT Registry Cloudswood   (United Kingdom)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

more..

Author keywords

Autologous transplantation; Relapsed acute myeloid leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 33845260304     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.015     Document Type: Article

References (28)

1. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Eng J Med 341 (1999) 1051-1062
2. Burnett A.K. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol. 6 (2002) 26-45
3. Leopold L.H., and Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leukemia Lymphoma 43 (2002) 715-727
4. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace relapse after autologous bone marrow transplantation. Lancet 341 (1993) 85-86
5. Meloni G., Vignetti M., Avvisati G., et al. BAVC regimen and autograft for acute myelogenous leukaemia in second complete remission. Bone Marrow Transplant 18 (1996) 693-698
6. Tomas F., Gomez-Garcia de Soria V., Lopez-Lorenzo J.L., et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: importance of duration of first complete remission in final outcome. Bone Marrow Transplant 17 (1996) 979-984
7. Gorin N.C., Aegerter P., Auvert B., et al. Autologous bone marrow transplantation for AML in first remission: a European survey of the role of marrow purging. Blood 75 (1990) 1606-1614
8. Gorin N.C., Labopin M., Fouillard L., et al. Retrospective evaluation of autologous bone marrow transplantation versus allogeneic bone marrow transplantation from an HLA-identical related donor in acute myelocytic leukaemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 18 (1996) 111-117
9. Lazarus H.M., Perez W.S., Klein J.P., et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 132 (2006) 755-769
10. Meloni G., Diverio D., Vignetti M., et al. Autologous bone marrow transplantation for acute promyelocytic leukaemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90 (1997) 1321-1325
11. Lo Coco F., Diverio D., Avvisati G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94 (1999) 2225-2229
12. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood 92 (1998) 2322-2333
13. R Development Core Team. R: a language and environment for statistical computing (2005), R Foundation for Statistical Computing, Vienna, Austria
14. Therneau T., and Lumley T. Survival: Survival analysis, including penalized likelihood. R package, version 2.18 (2005), R Foundation for Statistical Computing, Vienna, Austria
15. Gray B. cmprsk: subdistribution analysis of competing risks. R package, version 2.15 (2004), R Foundation for Statistical Computing, Vienna, Austria
16. Linker C.A., Damon L.E., Ries C.A., et al. Autologous stem cell transplantation for advanced AML. Bone Marrow Transplant 29 (2002) 297-301
17. Craddock C., Tauro S., Moss P., et al. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 129 (2005) 18-34
18. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
19. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
20. Martino R., Caballero M.D., Perez Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
21. Sayer H.G., Kroger M., Beyer J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31 (2003) 1089-1095
22. Taussig D.C., Davies A.J., Cavenagh J.D., et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukaemia after reduced-intensity allografting. J Clin Oncol 21 (2003) 3060-3065
23. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years of age. Blood 102 (2003) 3052-3059
24. Ho A.Y.L., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
25. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukaemia and myelodysplasia. J Clin Oncol 23 (2006) 9387-9393
26. Yeager A.M., Kaizer H., Santos G.W., et al. Autologous bone marrow transplantation in patients with acute nonlymphoblastic leukaemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315 (1986) 141-147
27. Rowley S.D., Lohen M., Radich J., et al. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant 21 (1998) 1253-1262
28. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454